Neipomax (filgrastim biosimilar)
/ Pharmstandard
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 30, 2026
Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Blokhin's Russian Cancer Research Center
New P2 trial • Germ Cell Tumors • Oncology • Ovarian Cancer • Testicular Non-seminoma
1 to 1
Of
1
Go to page
1